Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug
- 1 Jouf University, Saudi Arabia
- 2 Cairo University, Egypt
Abstract
The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
DOI: https://doi.org/10.3844/ajbbsp.2021.205.207
Copyright: © 2021 Mohamed Nabil Ibrahim and Abdo Abdellah Elfiky. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- 2,945 Views
- 1,354 Downloads
- 0 Citations
Download
Keywords
- Sofosbuvir-COVID-19-RNA Polymerase-Therapy